Treatment of Children with Juvenile Rheumatoid Arthritis

Publisher Website
Google Scholar
Abstract
AN article in this week's issue of the Journal, entitled "Penicillamine and Hydroxychloroquine in the Treatment of Severe Juvenile Rheumatoid Arthritis: Results of the U.S.A.-U.S.S.R. Double-Blind Placebo-Controlled Trial," concludes that in the presence of a nonsteroidal antiinflammatory drug, neither agent is superior to placebo in the treatment of the disorder.1 Juvenile rheumatoid arthritis comprises a group of childhood diseases characterized by chronic arthritis affecting peripheral joints with varying degrees of severity or by systemic involvement, with an unpredictable course.2 The basic treatment regimen consists of a nonsteroidal antiinflammatory drug and supportive programs such as physical therapy. If the patient . . .